07.21.14
All American Pharmaceutical & Natural Foods Corporation (AAP), Billings, MT, received an $80,000 grant from the Montana Department of Commerce, Montana Board of Research & Commercialization Technology to fund one of its current research projects, “KarboLyn A Unique Homopolysaccharide Compound for Glycogen Repletion in Athletes.” The Montana program supports local economic development by investing in research projects that present a clear path to commercialization.
“We’re grateful for the state support of our business through this research grant,” commented Jeff Golini, AAP, CEO & executive scientist. “This investment will allow us to field research to further our product development and expand our business.”
The research study is being fielded to determine the absorption efficiency of KarboLynvs. glucose and to assess the effects on energy levels over time. In the double-blind, placebo-controlled study, participants will have their glycogen levels monitored while using a treadmill. The company anticipates reporting on and publishing the study results in 2015.
This is the fourth grant AAP has received from the Montana Department of Commerce in the past 10 years. The other funding was granted for the commercialization of its proprietary products Kre-Celazine and Lyzme5.
“We’re grateful for the state support of our business through this research grant,” commented Jeff Golini, AAP, CEO & executive scientist. “This investment will allow us to field research to further our product development and expand our business.”
The research study is being fielded to determine the absorption efficiency of KarboLynvs. glucose and to assess the effects on energy levels over time. In the double-blind, placebo-controlled study, participants will have their glycogen levels monitored while using a treadmill. The company anticipates reporting on and publishing the study results in 2015.
This is the fourth grant AAP has received from the Montana Department of Commerce in the past 10 years. The other funding was granted for the commercialization of its proprietary products Kre-Celazine and Lyzme5.
